Teva Pharmaceutical Industries Total Long-Term Assets 2010-2024 | TEVA

Teva Pharmaceutical Industries total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
  • Teva Pharmaceutical Industries total long-term assets for the quarter ending September 30, 2024 were $29.445B, a 3.97% decline year-over-year.
  • Teva Pharmaceutical Industries total long-term assets for 2023 were $30.993B, a 3.03% decline from 2022.
  • Teva Pharmaceutical Industries total long-term assets for 2022 were $31.96B, a 8.93% decline from 2021.
  • Teva Pharmaceutical Industries total long-term assets for 2021 were $35.094B, a 6.75% decline from 2020.
Teva Pharmaceutical Industries Annual Total Long-Term Assets
(Millions of US $)
2023 $30,993
2022 $31,960
2021 $35,094
2020 $37,635
2019 $44,005
2018 $46,889
2017 $55,233
2016 $75,829
2015 $35,835
2014 $32,024
2013 $33,788
2012 $34,254
2011 $35,689
2010 $26,110
2009 $21,669
Teva Pharmaceutical Industries Quarterly Total Long-Term Assets
(Millions of US $)
2024-09-30 $29,445
2024-06-30 $29,706
2024-03-31 $30,475
2023-12-31 $30,993
2023-09-30 $30,663
2023-06-30 $31,007
2023-03-31 $31,956
2022-12-31 $31,960
2022-09-30 $32,800
2022-06-30 $33,767
2022-03-31 $34,607
2021-12-31 $35,094
2021-09-30 $35,698
2021-06-30 $36,374
2021-03-31 $36,603
2020-12-31 $37,635
2020-09-30 $37,576
2020-06-30 $42,210
2020-03-31 $42,446
2019-12-31 $44,005
2019-09-30 $44,704
2019-06-30 $45,618
2019-03-31 $46,422
2018-12-31 $46,889
2018-09-30 $51,180
2018-06-30 $52,319
2018-03-31 $54,494
2017-12-31 $55,233
2017-09-30 $69,856
2017-06-30 $71,760
2017-03-31 $76,441
2016-12-31 $75,829
2016-09-30 $81,361
2016-06-30 $39,576
2016-03-31 $38,132
2015-12-31 $35,835
2015-09-30 $36,125
2015-06-30 $37,072
2015-03-31 $31,240
2014-12-31 $32,024
2014-09-30 $32,686
2014-06-30 $33,188
2014-03-31 $33,444
2013-12-31 $33,788
2013-09-30 $33,944
2013-06-30 $33,412
2013-03-31 $33,653
2012-12-31 $34,254
2012-09-30 $34,597
2012-06-30 $34,656
2012-03-31 $35,503
2011-12-31 $35,689
2011-09-30 $28,260
2011-06-30 $27,559
2011-03-31 $27,201
2010-12-31 $26,110
2010-09-30 $22,949
2010-06-30 $17,120
2010-03-31 $17,703
2009-12-31 $17,903
2009-09-30 $17,975
2009-06-30 $17,490
2009-03-31 $17,610
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.384B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00